The Joint Corp (JYNT) - Rasio rega marang prakiraan pendapatan
The Joint Corp. (JYNT) dominance in the affordable spinal therapy niche and licensing barriers ensure stable positioning, as confirmed by the forward price-to-sales valuation chart. The value of 1.00 marks a new level. A decentralized franchising network reduces operational risks, while the shift toward organic expansion instead of costly acquisitions strengthens liquidity, creating a foundation for stable performance growth.
The Joint - rincian analitis lan metrik utama (JYNT)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas The Joint Corp.|JYNT - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas The Joint Corp.|JYNT - Tanggungan utang kumulatif perusahaan|Utang marang nilai buku The Joint|JYNT - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan The Joint Chiropractic|Likuiditas cepet thejoint.com
- data bathi bisnis lan rasio investasi:
JYNT - Penghasilan resik perusahaan|Bathi sing dikarepake The Joint Corp.|JYNT - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep The Joint Corporation|JYNT - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan The Joint|JYNT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan The Joint Chiropractic|JYNT - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan thejoint.com|JYNT - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep The Joint Corp.
- rincian pendapatan lan dodolan:
Analisis umum perusahaan:The Joint Chiropractic (JYNT)
Investors use this ratio to assess the market value of a business relative to expected sales to determine if an asset is overbought during periods of stagnation. The ratio of market capitalization to projected revenue for The Joint Corp. (JYNT) reflects the resilience of the franchising model to costs, where licensing barriers and brand scale create a defensive moat, a fact clearly confirmed by the forward price-to-sales valuation trend.
Pesaing wigati
HCA Healthcare - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan THC|FMS - Rasio rega marang prakiraan pendapatan|Solventum Health - Rasio rega marang pendapatan sing dikarepake|Encompass Health (EHC) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Universal Health Services, Inc. (UHS)|DVA (DaVita) - Multiplikator Forward P/S|RadNet Inc (RDNT) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Option Care Health Inc (OPCH)|Surgery Partners Group - Kapitalisasi marang prakiraan pendapatan|Premier, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake EYE (nationalvision.com)|PGNY: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARDT (Ardent Health)|SEM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Astrana Corp|Rasio rega marang prakiraan pendapatan Pediatrix Corp|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep US Physical Therapy Inc USPH|Rasio rega marang prakiraan pendapatan The Pennant Group (PNTG)|ORGO (Organogenesis Holdings Inc.) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Nutex Health Corp NUTX|AUNA (Auna Corp) - Rega mangsa ngarep marang pendapatan|SBC: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake evolus.com EOLS|Community Health Systems, Inc. (CYH) - Rasio rega marang prakiraan pendapatan|SKIN: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan MDWD|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Biote Corporation BTMD|Rasio rega marang prakiraan pendapatan DocGo Inc. (DCGO)|p3hp.org - Kapitalisasi marang prakiraan pendapatan|Gain Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake EUDA (EUDA Health Holdings)|BMGL: Multiplikator forward rega marang pendapatan|CollPlant Biotechnologies - Rasio rega marang pendapatan sing dikarepake|Cuprina Holdings (Cayman) Ltd (CUPR) - Rasio rega marang prakiraan pendapatan|concordmedical.com - Rega forward marang dodolan|AMS (American Shared Hospital Services) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MEDIROM Healthcare Group Inc. MRM|Multiplikator Forward P/S ALBT|Multiplikator Forward P/S DIH Group (DHAI)|Longevity Health Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake NIVF (newgenivf.com)|ATIP - Rasio rega marang prakiraan pendapatan|CareMax Inc. (CMAX) - Multiplikator forward rega marang pendapatan|KDLY: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ModivCare Corp (MODV)|Rasio rega marang prakiraan pendapatan Novo Integrated Sciences|Kapitalisasi marang prakiraan pendapatan SSY (SunLink Health Systems, Inc)|Multiplikator forward rega marang pendapatan BACK (IMAC Holdings)
